Werfen’s Post

Getting ready for the 14th International Congress on Autoimmunity in Ljubljana, where we'll have a great representation of the Werfen Autoimmunity R&D team! Hope to see you at our industry session where some of the hot topics in autoimmune biomarkers will be discussed. #precisionmedicine #autoimmunity #biomarkers #autoantibodies

Will you or a colleague be at next week's World Orphan Drug Congress in Boston?  Several of my Real Chemistry colleagues will be there, including my amazing manager Lindsay Cardinal Murphy! They'd love to meet up with anyone interested in talking about how advanced analytics and ecosystem-wide thinking can help advance the commercialization of rare disease therapies. Stop by the Real Chemistry booth (#632) for conversation and a chance to win a pair of Bose wireless headsets. Catch my colleagues' keynote panel conversation on Wednesday, April 24: "𝗙𝗿𝗼𝗺 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗳𝗶𝗻𝗱𝗶𝗻𝗴 𝘁𝗼 𝗽𝗮𝘆𝗲𝗿 𝗽𝘂𝗹𝗹-𝘁𝗵𝗿𝗼𝘂𝗴𝗵: 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗮𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀 𝘁𝗼 𝗳𝘂𝗲𝗹 𝘁𝗵𝗲 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻." It should be a great conference! #WorldOrphanUSA #marketaccess #raredisease #RWD #marketresearch

As healthcare marketers, understanding the evolving landscape of R&D in chronic diseases is paramount. Immunic, Inc. is set to host a Multiple Sclerosis R&D Day on September 10, featuring insights from industry leaders on innovative therapies like vidofludimus calcium. With participation in key scientific conferences throughout September, this is an opportunity to grasp emerging trends and strategic directions in MS treatment. Mark your calendars! #HealthcareMarketing #MSResearch #Immunic

This is one of the reasons I would love to work in the field of clinical trials. If there are 𝗻𝗼 𝗼𝘁𝗵𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝘁𝗶𝗼𝗻𝘀 𝗹𝗲𝗳𝘁, you can provide new hope. Each patient deserves to be treated. Results like these, where 𝟯 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 are still undergoing treatment after more than a year (see at 5.13 min in the video) , show the potential of this combination therapy. Usually not common in 2nd line cancer clinical trials. 𝗞𝘂𝗱𝗼𝘀 and 𝗰𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 to the extremely talented Medivir AB Team!  𝗟𝘆𝗰𝗸𝗮 𝘁𝗶𝗹𝗹 for your 𝗽𝗵𝗮𝘀𝗲 𝟮𝗯 trial. #clinicaltrials #Livercancer #Oncologyresearch #Medicalinnovation #Biotech

In 2024, new paths are being uncovered in endometriosis care. From advanced treatments to cutting-edge diagnostics, let's explore the promising insights into endometriosis research and the possible challenges ahead. #womensawarenessmonth https://hubs.li/Q02r4Wpf0

Kicking off the Xogene Summit 2024 with Rebecca Williams giving insight into US policies on Clinical Trial Transparency and a look at what to expect in the future.

Bronchiectasis is a lung condition more common in the UK than Parkinson’s or MS, yet instead of being a household name, we know very little about how it develops and progresses. Incredibly, the world’s first dedicated treatment (brensocatib) for bronchiectasis has just shown positive results in its Phase 3 clinical trial – meaning that this new drug reduced flare-ups and slowed the progression of the condition in people taking part. This research led by Professor James Chalmers and the team is an amazing leap forward for people with lung conditions, but we can’t stop there. We need to build on the momentum of this incredible discovery. That’s why this #WorldBronchiectasisDay we’re raising awareness with LifeArc of the impact of this lung condition. By working together, we can understand how best to invest in research and make the most of the real opportunity to change the way this condition is treated and managed.

Today is #worldbronchiectasisday a condition that is still poorly understood with no approved therapies. Recent data from EMBARC, the largest series of people with bronchiectais worldwide, highlighted that airway clearance is prescribed primarily on the basis of geographical location, not evidence. This is a huge burden to put on families. Insmed Incorporated’s brenscotanib maybe closer to approval but there is still much to understand about the respiratory microbiome and the role of potential modulators. Cystic fibrosis and primary ciliary dyskinesia are both neutrophilic endotypes of bronchiectasis. While CF has modulators that address 90% of the population, PCD has worse outcomes in children, an inequitable standard of care and no approved therapies. Both populations could be combined to better understand antimicrobilal resistance. #bronchiectasis #bronchiectasisneedsmore #primaryciliarydyskinesia

ACRO's annual meeting was a great opportunity to reflect on the contributions that the clinical research and technology member companies of ACRO have made to advancing the development and delivery of new therapies for patients around the world in 2024. A highlight of the meeting was a video interview between ACRO Board Chair Peyton Howell and FDA Commissioner Dr. Robert Califf reflecting on the agency's efforts to streamline regulatory processes and drive clinical trial innovation.   Dr. Califf's call to action for clinical research: 💠 Rethink global trial distribution 💠 Improve rare disease study methods 💠 Develop robust data models for real-world evidence 💠 Engage in potential FDA reforms.   #ACRO #FDA Learn more about ACRO's 2024 activities: https://lnkd.in/gZm2vasr

Join the conversation!